BCAL Diagnostics (ASX:BDX) Net Income (Continuing Operations): A$-7.37 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is BCAL Diagnostics Net Income (Continuing Operations)?

BCAL Diagnostics ASX:BDX Net Income (Continuing Operations) is A$-7.37 Mil as of Jun. 2026. The stock has 5 warning signs investors should review.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. BCAL Diagnostics's Net Income (Continuing Operations) for the six months ended in Jun. 2026 was A$-3.45 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2026 was A$-7.37 Mil.

BCAL Diagnostics  (ASX:BDX) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

BCAL Diagnostics Net Income (Continuing Operations) Related Terms

BCAL Diagnostics Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for BCAL Diagnostics's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BCAL Diagnostics Net Income (Continuing Operations) Chart

BCAL Diagnostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25 Jun26
Net Income (Continuing Operations)
-3.39 -5.06 -6.40 -7.24 -7.37

BCAL Diagnostics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -3.99 -4.00 -3.24 -3.92 -3.45

BCAL Diagnostics Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-7.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of A$-7.37 Mil mean?
BCAL Diagnostics (ASX:BDX) has a Net Income (Continuing Operations) of A$-7.37 Mil as of Jun. 2026. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on BCAL Diagnostics and its competitors.
Is BCAL Diagnostics' Net Income (Continuing Operations) too high?
BCAL Diagnostics' current Net Income (Continuing Operations) is A$-7.37 Mil.
How does BCAL Diagnostics' Net Income (Continuing Operations) compare to TMO and DHR?
BCAL Diagnostics' Net Income (Continuing Operations) of A$-7.37 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Medical Diagnostics & Research company?
A good Net Income (Continuing Operations) depends on the Medical Diagnostics & Research industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on BCAL Diagnostics and its competitors. BCAL Diagnostics's current Net Income (Continuing Operations) is A$-7.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BCAL Diagnostics stock overvalued right now?
BCAL Diagnostics (ASX:BDX) has a current Net Income (Continuing Operations) of A$-7.37 Mil. The current Net Income (Continuing Operations) is A$-7.37 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For BCAL Diagnostics (ASX:BDX), the current Net Income (Continuing Operations) is A$-7.37 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BCAL Diagnostics Business Description

Address 50 Clarence Street, Suite 506, Level 5, Sydney, NSW, AUS, 2000
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost-effective, accurate, and available to all women regardless of age, race, and geographic location.